Last reviewed · How we verify

Emdogain (EMD) - test

Universidad Complutense de Madrid · FDA-approved active Biologic

Emdogain is a protein extract derived from developing tooth buds that promotes periodontal regeneration by stimulating growth factors and extracellular matrix formation.

Emdogain is a protein extract derived from developing tooth buds that promotes periodontal regeneration by stimulating growth factors and extracellular matrix formation. Used for Periodontal defects and bone loss associated with chronic periodontitis, Intrabony defects requiring periodontal regeneration.

At a glance

Generic nameEmdogain (EMD) - test
SponsorUniversidad Complutense de Madrid
Drug classRegenerative biologic / Enamel matrix derivative
TargetEnamel matrix proteins (EMPs); indirect effects on growth factors and cell signaling pathways
ModalityBiologic
Therapeutic areaDentistry / Periodontics
PhaseFDA-approved

Mechanism of action

Emdogain contains enamel matrix proteins (EMPs) that mimic the natural developmental signals present during tooth formation. When applied to periodontal defects, these proteins stimulate fibroblast proliferation, cementum formation, and periodontal ligament regeneration, facilitating the restoration of lost periodontal tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: